Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

3-FPM

3-FPM molecule structure3-FPM molecule structure
3-Fluorophenmetrazine
PAL-593, 3-FPH, 3F-PhenmetrazineOpen in Piru
Psychoactive Class

3-FPM is a stimulant and a fluorinated derivative of phenmetrazine.1 3-FPM appeared on the drug market in 2014.1 Users often describe its stimulation as relatively subtle, with less nervousness, insomnia, and euphoria than other stimulants. It is classified as habit-forming, and some anecdotal reports describe serious nervous system reactions in people who use it.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold5 mg
Light10-20 mg
Moderate20-35 mg
Strong35-50 mg
Heavy50+ mg

Duration

Onset5 minutes
Total3-6 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

The physical effects of 3-FPM can be broken down into several components which progressively intensify proportional to dosage.

Increased perspirationVasoconstriction

Cognitive

The cognitive effects of 3-FPM can be broken down into several components which progressively intensify proportional to dosage. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate doses, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.

Forked from Subjective Effect Documentation byJosie Kins September 2015.

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Mandelin(MD)
yellow2 → orange2 → red2
Liebermann(LB)
white → yellow2 → orange2
Gallic(GA)
pink1
Morr(MO)
pink2 → green1
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

3-FPM primarily releases norepinephrine and dopamine by reversing their transporters, moving these neurotransmitters from inside cells into the extracellular space. It has negligible efficacy as a serotonin releaser. In HEK293 cells, it also inhibits dopamine and norepinephrine uptake,2 with substantially weaker inhibition of serotonin uptake.3

Pharmacokinetics

3-FPM undergoes N-oxidation, hydroxylation of its aromatic ring followed by O-methylation, and hydroxylation and oxidation of its alkyl portion.4 Breakdown of the ethyl bridge produces a metabolite with both O- and N-dealkylation.4 These transformations can occur in combination, followed by glucuronidation or sulfation.4

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholDXMDissociativesMAOIsMDMAMXENBOMe compoundsStimulantsTramadol
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Repeated use over an extended period can produce tolerance to many of 3-FPM's effects, with larger doses needed to obtain the same response; no timeframe for full tolerance is specified. Across several sessions, diminishing rewarding effects and increasing body load have also been reported, with dose escalation providing limited additional positive effects.
Baseline Reset
Tolerance returns to baseline within approximately 1–2 weeks if no further 3-FPM is consumed.5
Half Tolerance
Tolerance falls to approximately half its previous level within 3–7 days if no further 3-FPM is consumed.
Cross Tolerance

All dopaminergic stimulants

Harm Potential

Addiction & Dependence

Psychological

Moderate

Chronic 3-FPM use is moderately addictive, with high abuse potential and psychological dependence in some users; cravings and withdrawal effects may follow abrupt cessation once addiction develops. Repeated redosing and escalating consumption despite diminishing reward have also been reported.

Toxicity

Lethal Dosage

The toxic dose of 3-FPM is unknown.

Immune system

Several users have reported severe flu-like symptoms during the comedown from 3-FPM, including muscle and joint pain, fever, chills, and headaches, sometimes accompanied by migraine auras; systemic inflammation is a proposed explanation, with causality uncertain.

History & Culture

3-FPM was developed as an analogue of phenmetrazine6, which was used clinically as an appetite suppressant in Europe in the…

Legality

International

3-FPM is not named in the INCB lists of narcotic drugs under the 1961 Convention or psychotropic substances under the 1971 Convention. It is also not named in the precursor tables of the 1988 Convention.

By Country

Illegal14
United States flagUnited StatesIllegal (analog/blanket ban)
Argentina flagArgentinaIllegal
Australia flagAustraliaIllegal (analog/blanket ban)
Austria flagAustriaIllegal (analog/blanket ban)
Brazil flagBrazilIllegal
Czech Republic flagCzech RepublicIllegal
Germany flagGermanyIllegal (analog/blanket ban)
Israel flagIsraelIllegal
Netherlands flagNetherlandsIllegal (analog/blanket ban)
Poland flagPolandIllegal
Singapore flagSingaporeIllegal
Sweden flagSwedenIllegal
Switzerland flagSwitzerlandIllegal
Ukraine flagUkraineIllegal
Controlled / restricted2
Ireland flagIrelandRestricted
United Kingdom flagUnited KingdomRestricted
Not scheduled3
France flagFranceNot scheduled
India flagIndiaNot scheduled
Spain flagSpainNot scheduled

References

Source Pages

  1. Drug Users Bible by Dominic Milton Trott
  2. Erowid Novel Drug Briefs: 3-FPM
  3. Erowid: 3-FPM Vault
  4. Erowid: 3F-Phenmetrazine Vault
  5. Isomer Design (TiHKAL/PiHKAL)
  6. PsychonautWiki
  7. The Drug Classroom
  8. TripSit Factsheet: 3-FPM
  9. TripSit Factsheets
  10. Wikipedia
  11. Wikipedia: 3 Fluorophenmetrazine

Citations

  1. Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). Drug Testing and Analysis (2019). https://doi.org/10.1002/dta.257712
  2. Critical Review Report: 3-Fluorophenmetrazine — WHO Expert Committee on Drug Dependence, Forty-third Meeting. cdn.who.int (n.d.). https://cdn.who.int/media/docs/default-source/controlled-substances/43rd-ecdd/3-fluorophenmetrazine-a.pdf123
  3. Fluorinated phenmetrazine ‘legal highs’ act as substrates for high-affinity monoamine transporters of the SLC6 family. Neuropharmacology (2018). https://doi.org/10.1016/j.neuropharm.2017.10.00612
  4. 3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques. Journal of Pharmaceutical and Biomedical Analysis (2016). https://doi.org/10.1016/j.jpba.2016.06.011123
  5. 3-fluorophenmetrazine – a new psychoactive substance on the Polish drug market. Problems of Forensic Sciences (2016). https://arch.ies.gov.pl/images/PDF/2016/vol_105/105_Adamowicz.pdf1
  6. Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers. researchonline.ljmu.ac.uk (n.d.). https://researchonline.ljmu.ac.uk/id/eprint/3143/1/DTA-15-0338.R1_accepted_uncorrected.pdf1
  7. Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its /ortho- and /para-substituted isomers: Synthesis and characterization of fluorophenmetrazine positional isomers. Drug Testing and Analysis (2017). https://doi.org/10.1002/dta.19451
  8. Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). Drug Testing and Analysis (2019). https://doi.org/10.1002/dta.25771
  9. Narcotic Drugs and Psychotropic Substances Act, 1985, Schedule, as last amended by S.O. 906(E) (18 February 2026). indiacode.nic.in (n.d.). https://www.indiacode.nic.in/bitstream/123456789/6834/1/narcotic-drugs-and-psychotropic-substances-act-1985.pdf1
  10. Narcotic Drugs and Psychotropic Substances Act, 1985, Schedule, as last amended by S.O. 906(E) (18 February 2026). cbn.gov.in (n.d.). https://www.cbn.gov.in/hi/notifications/circulars_notifications/1

Further Reading

  1. Backberg et al. 2016 - Adverse events related to 3-FPM (STRIDA project)
  2. Blough et al. 2011 - Phenylmorpholines patent
  3. Gibbons et al. 2016 - Emerging NPS in the United Kingdom
  4. Mayer et al. 2017 - Acute kidney injury and limb ischaemia with 3-FPM
  5. Pifl et al. 2017 - Fluorinated phenmetrazine as monoamine transporter substrates
  6. Soh & Elliott 2014 - Phenmetrazine pharmacology review
  7. Welter et al. 2017 - 3-FPM metabolism and biotransformation

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 3-FPM article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.